1. Introduction {#s0005}
===============

Ketamine has been identified as a rapidly acting antidepressant ([@bb0045]; [@bb0525]; [@bb0305]). The different properties of ketamine, including the cardiovascular side-effects ([@bb0420]), are likely to arise due to its influence on multiple receptor types. Inhibition of the NMDA receptor as the primary mechanism of antidepressant action ([@bb0065]) has recently been challenged ([@bb0520]). Instead, changes in synaptic plasticity, relevant for the development of major depressive disorder (MDD), may be influenced by ketamine via factors such as AMPA receptor mediated elevation of brain-derived neurotrophic factor (BDNF) levels ([@bb0130]; [@bb0540]). While these mechanisms may explain long-term effects of ketamine, more research is necessary to reveal the pathways mediating acute ketamine effects, including other neurotransmitter systems ([@bb0495]). Understanding the mechanisms underpinning the acute response to ketamine is particularly important, because the acute side-effects of ketamine have been proposed to be predictive of its long-term antidepressant effects ([@bb0235]).

We focus on the known influence of ketamine on the norepinephrine system as a potential mechanism by which ketamine has an acute effect on brain function. Firstly, the acute effects of ketamine on blood pressure and heart rate are considered to be driven by the norepinephrine system ([@bb0035]). Specifically, ketamine is known to inhibit the norepinephrine transporter (NET), as shown by in vitro experiments and in vivo studies in animals and humans ([@bb0035]; [@bb0275]; [@bb0125]; [@bb0160]; [@bb0325]; [@bb0165]; [@bb0535]). Importantly, those effects are observed at plasma concentrations achievable with administration of subanaesthetic doses ([@bb0275]; [@bb0315]). We have described this relationship in more detail previously ([@bb0225]). The NET is responsible for the recirculation of norepinephrine (NE) from the synaptic cleft into the presynaptic terminal ([@bb0410]). The study of different NET genotypes provides an approach to exploring the role of NET in the antidepressant effects of ketamine. Indeed, one common *NET* polymorphism (rs28386840) has been associated with the severity of the ketamine-related initial blood pressure increase, indicating an acute influence of ketamine on the peripheral norepinephrine system ([@bb0225]).

In the brain, the highest concentrations of NET have been found in the locus coeruleus (LC) ([@bb0405]; [@bb0020]) as well as in the medial thalamus ([@bb0450]). The LC is a small bilateral nucleus located at the bottom of the fourth ventricle in the brainstem. It is the main source of norepinephrine in the brain ([@bb0300]) and projects to nearly the whole brain, including the limbic system and prefrontal cortex. LC activity plays an important role in controlling autonomic functions ([@bb0395]) as well as in arousal and attention.

Human attention has been linked to the activity of three networks, each of which has been implicated in different attentional phases: the alerting network, the orienting network, and the executive control network ([@bb0080]; [@bb0140]; [@bb0085]; [@bb0145]; [@bb0370]). Within these concepts, the LC has been assigned to all three networks, but its relevance has been mostly emphasized in the *alerting network*, with a pronounced role in the "alerting effect" ([@bb0370]).

Acute ketamine administration has a rapid impact on attention ([@bb0340]). For example, ketamine resulted in an elevated false alarm rate and a reduced hit rate in a visual oddball task ([@bb0310]). Analogously, it also acutely impaired performance in the AX-CPT arousal task, in which a lower hit rate and an elevated context-dependent false alarm rate were reported following ketamine administration ([@bb0455]). In rats, ketamine evoked a response-depressing effect in the five-choice serial-reaction time task, shown by an increased number of omissions and a reduced response speed, without affecting motivation ([@bb0320]).

Animal studies indicate that ketamine influences LC function ([@bb0105]; [@bb0135]), and human studies show that the event-related potential P300 wave -- which has been linked to phasic LC activity ([@bb0085]) -- has a reduced amplitude during an attentional response following ketamine ([@bb0340]; [@bb0310]).

The LC is thus involved in both blood pressure homeostasis and in attention regulation and vigilance, potentially drawing together two of the acute effects of ketamine and suggesting that effects on the norepinephrine system may underlie both.

We therefore propose that ketamine has an influence on the LC via inhibition of the NET, leading to elevation of NE concentration in the synaptic clefts. This elevation leads to change in the resting state functional connectivity (rs-fc) of the LC within the alerting network, reflecting a more distractible state of arousal. Consequently, we also predict an influence of the NET genotype on functional connectivity change after ketamine.

Despite the indications presented here, most studies have assessed acute ketamine effects based on the hypothesis of a mechanism involving NMDA-receptors, and to date, no study has investigated the influence of ketamine on brain structures that are linked to the norepinephrine network, including the NET.

2. Methods {#s0010}
==========

2.1. Subjects {#s0015}
-------------

The study was conducted as a double-blind, placebo-controlled, randomized parallel-design trial. 80 participants (33 women, 25.89 ± 5.29) were recruited by public advertisement and received financial award for their participation. The participants were in a state of good general health as determined by medical history, physical examination, blood laboratory tests, electrocardiography and toxicology findings. Participants with magnetic resonance imaging (MRI)-incompatible devices, regular medication or excessive caffeine intake and current or former drug abuse were excluded. All subjects completed the Mini International Neuropsychiatric Interview (M.I.N.I., German Version 5.0.0) ([@bb0005]) and underwent additional interview by the study physician to rule out any DSM-IV psychiatric disorders. The study was approved by the institutional ethical review board of the University of Magdeburg, and all subjects gave written informed consent in accordance with the Declaration of Helsinki.

3. Study design {#s0020}
===============

After a baseline MRI session, study participants were randomized to a 50 ml intravenous infusion of either 0.5 mg/kg racemic ketamine (Ketamine-ratiopharm 500 mg/10 ml) or saline (Berlin-Chemie Isotone NaCl 0.9%) outside the MRI scanner. The infusion was administered over 40 min via an infusion pump (Injectomat 2000, Fresenius Kabi GmbH) in a resting, supine position. Twenty minutes after the infusion was completed (duration of infusion 40 min), a post-infusion MRI session was conducted. Each MRI session lasted 60 min with collection of 13 min rs data after a 40 min spectroscopy run.

The whole study included other time points (i.e. 24 h MR session). Since our hypothesis was specific for acute effects on the NE system, we focused on the baseline and 1 h functional MRI (fMRI) data.

4. FMRI data acquisition, processing and analysis {#s0025}
=================================================

Image acquisition was performed using a 7 Tesla Magnetom scanner (Siemens) with the following parameters for T1 anatomical images: 3D-MPRAGE sequence, TE = 2.73 ms, TR = 2300 ms, T1 = 1050 ms, flip angle = 7°, bandwidth = 140 Hz/pixel, acquisition matrix = 320 × 320 × 224, isometric voxel size = 0.8 mm^3^. Resting state fMRI data were acquired eyes-closed and with the following parameters: 62 axial slices, acquisition matrix = 106 × 106, field of view = 212 × 212 mm, slice thickness = 2 mm, leading to a high resolution of 2 mm isotropic, repetition time (TR) = 2800 ms, echo time (TE) = 22 ms, flip angle = 80°, 280 volumes in total). Raw data quality was visually checked for each dataset and each time point. Subjects were excluded if artifacts were observed at any time point (Supplementary Fig. 1), which led to exclusion of 19 datasets, leaving 61 subjects for further analysis. Data preprocessing was conducted using scripts developed in the 1000 Functional Connectomes project ([https://www.nitrc.org/projects/fcon_1000/](https://www.nitrc.org/projects/fcon_1000){#ir0005}) with several modifications. This pipeline implemented motion correction, spatial smoothing with a Gaussian kernel (FWHM = 4 mm), temporal filtering with a bandpass filter (0.005--0.1 Hz) and removal of linear temporal trends, and regressed out the mean time course of white matter, cerebrospinal fluid and six affine motion parameters. No slice time correction was performed because of its minimal impact in task-free functional connectivity analysis at the TR used in this study ([@bb0500]), as well as our long acquisition time of 13 min. We additionally regressed out motion outliers identified by a framewise displacement (FD) \> 0.2 ([@bb0375]), calculated with fsl_motion_outliers in FSL.

As a confirmatory analysis, we additionally preprocessed the data with physiological noise regressors (heart beats and respiration), created with the FSL PNM toolbox ([@bb0070]). For this analysis, we excluded another eight subjects due to poor physiological data recordings.

The fMRI data of each subject were coregistered to the corresponding individual high-resolution anatomical images and then normalized to the Montreal Neurological Institute (MNI) template (ICBM152) with 2 × 2 × 2 mm^3^ resolution.

The seed was defined based on a previous probability template of LC ([@bb0190]). Two subjects were excluded because of a mismatch after registration, compared to the targeted probability template (Supplementary Fig. 2).

The calculation of rs-fc included extraction of the time series from the average LC seed, computation of voxel-wise correlations with the extracted time series, *Z*-transformation of the correlations and registration of the Z-transformed correlations to standard space using AFNI (<https://afni.nimh.nih.gov>/) and FSL (<https://fsl.fmrib.ox.ac.uk>/).

Calculation of second level statistics for the subjects that passed the preprocessing steps (ketamine group *n* = 29, 12 women; placebo group *n* = 30, 14 woman) was performed using SPM12 (<http://www.fil.ion.ucl.ac.uk/spm>). There was no age difference between the two treatment groups (t(57) = 0.810; *p* = .421).

Specific analysis steps: Statistic images were assessed for cluster-wise significance by using a cluster-defining threshold of *p* = .001. To investigate the baseline rs-fc from LC to all the brain, we conducted a one-sample *t*-test including both groups (ketamine, placebo) for the resting state scan before infusion. A mixed-design ANOVA was performed to assess the time (baseline, after ketamine or placebo infusion) by group (ketamine n = 29, placebo n = 30) interaction of the rs-fc of the LC to whole brain. As a post-hoc test, we conducted a paired-*t*-test within the ketamine and placebo groups with the factor time (baseline, one hour after ketamine administration) to investigate the change in rs-fc in each group on a whole brain level. To account for multiple testing (two groups), we defined a conservative *p* \< .025 for rejection of the H0 in both of these analyses. We then aimed to corroborate the result of the paired-t-test with the physiological noise corrected data using a small volume correction corresponding to regions of interest revealed by the interaction.

Genotyping of blood samples with regard to the NET gene rs28386840 was performed following a protocol published previously ([@bb0225]). To test the influence of genotype on rs-fc change, we extracted the change of the mean rs-fc beta-weights for the significant result in the ketamine group (baseline, directly after ketamine administration) and compared the groups (\[AA\] *n* = 15, \[T\]-carrier *n* = 13, no genetic data for one participant) using the non-parametric *U* Test for two independent samples. Regional activity was tested by the same analysis for the mediodorsal (MD) thalamic subregion based on WFU Pick-Atlas.

MRI figures were created with Mango (Research Imaging Institute, UTHSCSA) and the WFU Pick-Atlas ([@bb0245]).

5. Results {#s0030}
==========

The LC rs-fc at baseline showed connections with the cingulate cortex, temporal superior gyrus, putamen, caudate nucleus, pallidum, hippocampus, precuneus, thalamus, cerebellum and brainstem regions ([Fig. 1](#f0005){ref-type="fig"}**,** Supplementary Table 1**).**Fig. 1Baseline resting state functional connectivity (rs-fc) between locus coeruleus (LC) and the whole brain, across all patients in the placebo and ketamine groups (*p* \< .05, FWE cluster level corrected).Fig. 1

The whole brain ANOVA revealed a significant drug (ketamine, placebo) by time (baseline, 1 h after start of infusion) interaction in the bilateral thalamus (*n* = 59, *p* \< .001, cluster size k = 614, FWE cluster level corrected, [Fig. 2](#f0010){ref-type="fig"}).Fig. 2Whole-brain analysis of variance (ANOVA) revealed a significant time-by-group (baseline, 1 h; ketamine, placebo) interaction of resting state functional connectivity (rs-fc) between the locus coeruleus (LC) seed and the bilateral thalamus (*p* \< .001, FWE cluster level corrected, cluster size = 614).Fig. 2

Follow-up analysis showed that this interaction was driven by a rs-fc-decrease between the LC and the bilateral thalamus in the ketamine group (*n* = 29, *p* = .008, cluster size k = 252, FWE cluster level corrected, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}), which was not found in the placebo group. Further investigation of the thalamic nuclei revealed decreased rs-fc in the ventral anterior (VA), ventral lateral (VL) and mediodorsal nuclei bilaterally, and in the left ventral posterolateral (VPL) nucleus and the right centromedian nucleus (CM) ([Fig. 4](#f0020){ref-type="fig"}**,** Supplementary Table 2). There were no further significant findings.Fig. 3Decrease in resting state functional connectivity (rs-fc) from locus coeruleus (LC) to the thalamus following ketamine (*p* = .008, FWE cluster level corrected, cluster size = 252, Panel 1). Change in rs-fc between LC seed and thalamus in ketamine and placebo groups at baseline and 1 h after administration. Decrease of rs-fc is only significant in the ketamine group (p = .008, FWE cluster level corrected, Panel 2).Fig. 3Fig. 4Decrease in locus coeruleus (LC) resting state functional connectivity (rs-fc) to thalamic subnuclei in the ketamine group, axial view. Significant thalamus cluster (blue, MNI coordinates 4, −10, 0) including VA (yellow-green), VL (turquoise), MD (red), VPL (brown) nuclei and the right CM (smaller blue cluster). The overlap between the significant cluster and the thalamic subnuclei is marked in light blue. Numbers indicate the z-coordinate within the brain in MNI space.Fig. 4

In the dataset analyzed following the second preprocessing (controlling for physiological noise), a rs-fc reduction from LC to the thalamus was also identified (*p* = .018, FWE small volume peak level corrected).

The reduction of rs-fc between LC and thalamus was dependent on *NET* rs28386840, with a greater decrease in the \[AA\] homozygotes than in the \[T\] carriers (U = 55, *p* = .050, [Fig. 5](#f0025){ref-type="fig"}). In the MD nuclei of the thalamus, on which we focused due to previous detection of NET in the medial thalamus as well as the LC ([@bb0450]), the difference was even more pronounced (U = 54, *p* = .045).Fig. 5Differing changes in resting state functional connectivity (rs-fc) from locus coeruleus (LC) to thalamus in the ketamine group according to *NET* genotype (\**p* = .05).Fig. 5

6. Discussion {#s0035}
=============

Following subanaesthetic ketamine administration, we found a decrease in rs-fc between the LC and the thalamus peaking at the mediodorsal, ventral anterior, ventral lateral bilateral, left ventral posterolateral and right centromedian nucleus. Genetic evidence further suggested an underlying noradrenergic mechanism, as this decrease was modulated by the *NET* rs28386840 gene with a greater decrease in \[AA\] genotype than in \[T\] carriers.

These results are compatible with the proposed effects of ketamine on attention regulation, since the rs-fc change observed here concerns the first path of the associated attention network.

The thalamus has been classified as a bottom-up regulatory entity for alertness, with its activation interpreted as facilitating increased response readiness after an external warning stimulus ([@bb0360]). This effect is thought to support target detection and to improve awareness in tasks. Accordingly, the thalamus has been shown to be activated in the alerting effect ([@bb0140]), together with the LC ([@bb0505]).

Recent studies also describe the role of the thalamus in executive attentional control. Elevated alertness was associated with high activity in the thalamus, which was interpreted as increasing the signal-to-noise ratio and facilitating a reduction of distraction in attentional performance ([@bb0385]; [@bb0095]).

Furthermore, the attentional networks revealed by task-based studies show a strong overlap with networks identified in the resting condition ([@bb0150]; [@bb0470]), and an involvement of the thalamus has been shown in the resting-state "salience network" ([@bb0415]). The salience network has been suggested to constitute a core regulatory entity of human consciousness due to its responsibility for "higher-order" stimulus selection ([@bb0415]), and within this network, the MD has been shown to regulate behavioral flexibility ([@bb0345]; [@bb0365]).

The observed connectivity decrease between LC and thalamus could indicate a change in the regulation of arousal in terms of a disruption of the alerting function, a promotion of non-selective sensory signal detection and an enhancement of behavioral flexibility. We suggest that this disconnection within the attention network may constitute a neurophysiological correlate of the known ketamine-related impairment in attentional tasks ([@bb0215]; [@bb0455]; [@bb0340]; [@bb0310]). We postulate that this decoupling of LC-thalamic control with thalamic nuclei involved in attentional processing leads to more nonspecific sensory signal detection and a higher susceptibility to non-focused sensory signals in the thalamus. Conceptual work has explained the delusion-like symptoms after ketamine, which include disembodiment and impaired control of cognition ([@bb0475]), as stemming from reduced top-down signaling and increased bottom-up signaling ([@bb0090]; [@bb0380]). We suggest that the increased bottom-up signaling may be facilitated by the decrease of functional LC-thalamic connection found in our study.

Accordingly, the different roles of the thalamic nuclei that we found to be disconnected from LC are related to the well-recognized actions of ketamine regarding attentional performance and motor response ([@bb0310]), memory ([@bb0390]) and sensory signal perception ([@bb0475]). The right CM nucleus of the thalamus is directly related to attentional processing ([@bb0200]; [@bb0270]). The MD nucleus connects subcortical structures to the cortex and is anatomically connected with the LC ([@bb0285]). Evidence indicates that the MD is also involved in attention ([@bb0465]) and forms a part of the salience network ([@bb0415]). It is also involved in sexual arousal ([@bb0485]) and in memory processing ([@bb0010]; [@bb0440]). The VPL, as part of the ventral posterior nucleus, conducts sensory information from the ascending medial lemniscus to the primary and secondary somatosensory cortex areas ([@bb0040]). VA and VL nuclei are involved in motor circuits, including the preparation of movement ([@bb0260]; [@bb0185]).

Based on our observations of connectivity changes, it is intriguing to interpret our findings in terms of the underlying neuroanatomy and physiology of the LC norepinephrine system. The implicit prerequisite of directed connections is supported by anatomical and animal studies reporting effective connectivity between the LC and the thalamus ([@bb0395]). The firing mode of the thalamus is influenced by norepinephrine, which subsequently increases thalamic neuronal excitability and responsiveness, and is associated with particular vigilance states ([@bb0255]). More precisely, the different LC firing patterns directly influence the thalamic reaction to sensory stimuli ([@bb0050]). In line with the Adaptive Gain Theory ([@bb0025]), the different LC firing patterns have the capability either to promote non-selectively all sensory inputs to the thalamus or to facilitate selective responses observable in connectivity changes between LC, thalamus and sensory cortex ([@bb0115]). Aston-Jones expected an increase in false alarm errors, problems with discrimination between targets and a lower threshold for unspecific sensory stimuli with LC tonic activity ([@bb0025]; [@bb0085]), which is exactly what was found as an effect of ketamine administration ([@bb0340]; [@bb0455]; [@bb0310]; [@bb0320]).

We speculate that ketamine might influence the LC firing mode via inhibition of the NET, which shows its highest expression level in the LC. This inhibition would cause a local elevation of NE levels that could directly affect the LC self-regulating system ([@bb0395]; [@bb0330]) and influence LC firing modes.

The modulation of ketamine-related LC--thalamic rs-fc changes by a *NET* genetic variant with a greater response in \[AA\] homozygotes further supports the idea that the mechanism of action of ketamine involves these norepinephrine pathways. According to our hypothesis, \[T\] allele carriers would exhibit lower NET activity and thus decreased clearance of norepinephrine from the synaptic cleft ([@bb0195]; [@bb0410]). This suggests that differential NE levels are likely to constitute the distinctive element between the two groups. Neuronal network models of LC function relate high local NE levels in the LC to high tonic LC activity ([@bb0460]; [@bb0030]).

Accordingly, one would primarily expect an increased ketamine effect on rs-fc in the \[T\] allele carriers. However the overall mechanism needs to incorporate other, systemic effects, which occur at the same time. The \[T\] genotype is thought to have decreased promoter function ([@bb0195]), and accordingly, we found a stronger initial blood pressure rise in \[T\] carriers during ketamine administration ([@bb0225]). One hour after the start of the infusion, however, \[T\] carriers showed a lesser response in terms of LC-thalamic connectivity when compared to \[AA\] carriers. Blood pressure increase after administration of NET inhibitors likely results from two mechanisms: peripheral NE rise, which elevates blood pressure and -- to a lesser degree -- a centrally mediated counter regulation that lowers blood pressure ([@bb0330]). The LC tightly controls the sympathetic tone and influences short-term blood pressure homeostasis ([@bb0395]). A diminished change of LC tone in \[T\] carriers could conceptually be linked to a reduced central counter regulation in response to the increased initial blood pressure rise.

Contrary to these findings, another recent study indicated *highe*r NET availability in the thalamus ([@bb0425]) in healthy \[T\] carriers, supporting potential alternative explanations. More research considering the distinct underlying network dynamics is necessary to reveal the complex interactions between *NET* genetics, *NET* availability and function, and connectivity differences.

A connectivity decrease between the LC and thalamus, similar to the one found in our fMRI study, has also been shown measuring local cerebral glucose utilization in mice receiving ketamine ([@bb0105]). Ketamine was associated with an elevated mean firing rate in LC norepinephrine neurons in mice ([@bb0135]) -- which we would interpret as a shift to the non-specific arousal condition.

The current findings indicate that the mechanism underlying the antidepressant effect of ketamine may also involve the norepinephrine system. Previous research has shown that norepinephrine and the LC are substantially involved in broad depression-like behaviors and modulated by a wide range of antidepressant drugs ([@bb0290]). In animal studies, neuronal loss in the LC has resulted in depressive symptoms ([@bb0445]), and the regulation of LC firing modes is essential in stress vulnerability ([@bb0100]) and social defeat ([@bb0180]).

Consistent with our understanding, in a positron emission tomography (PET) study, higher NET availability in MDD patients compared to controls has been found in both the LC and in the thalamus, particularly in a thalamic subregion projecting to the frontal cortex ([@bb0295]). Moreover, visual attention was maintained in the MDD patients conducting the Trail Making Test and was positively correlated with NET availability ([@bb0295]).

Reducing alertness would counteract a hypothesized hyperalertness in MDD which has been found in electroencephalography (EEG) vigilance studies ([@bb0170]; [@bb0335]). MDD patients were not impaired in a visual attention task and performed even better than healthy controls in a study using the flanker task ([@bb0120]). Accordingly, reducing an increased attentional focus may be in line with a therapeutic mode of action based on a mechanism involving reduced LC-thalamic connectivity.

Taken together, it seems plausible that patients with MDD may have an altered alarm system with high NE levels in brain structures that are a functional part of this network and effectively innervated by the LC -- especially the medial thalamus. Long-term NE elevation could induce upregulation of the NET in the thalamus ([@bb0220]; [@bb0490]; [@bb0240]) and explain the observed elevated thalamic NET availability in MDD patients. Ketamine may acutely disrupt a long-term activated alarm mode of the LC. This hypothesis would be in line with recent ideas suggesting a reduction of arousal to treat depressive symptomatology, at least in a subset of MDD patients ([@bb0435]). Such a mechanism has been partly discussed with respect to other antidepressant mechanisms such as sleep deprivation, which convergingly also leads to very rapid antidepressant effects, similar to ketamine ([@bb0060]). Finally, beyond the antidepressant effect, a shift in attentional focus could relate to further acute effects of ketamine such as pain relief ([@bb0250]; [@bb0315]).

Since ketamine possesses a high affinity for NMDA receptors ([@bb0430]), and the thalamus was highlighted in the ketamine model of schizophrenia ([@bb0155]; [@bb0480]), NMDA receptor inhibition mediated thalamic-LC rs-fc change ([@bb0175]) could provide an alternative explanation for our results. To our knowledge, however, there is no evidence in the literature that the thalamus is a structure with high NMDA receptor density or enhanced ketamine NMDA receptor binding, which would support the hypothesis of a preferred NMDA receptor action on that structure in healthy volunteers, while our hypothesis is based on structural evidence for a particularly high NET density in the LC and thalamus ([@bb0405]; [@bb0020]; [@bb0450]). Interestingly, strong efferent projections from LC to thalamus have been found ([@bb0395]) to influence sensory signal perception in the thalamus ([@bb0110]), whereas no known "top-down" control from thalamus to LC exists. Moreover, the known sympathomimetic cardiovascular side-effects of ketamine reflect the relevance of its NET inhibitory component. In contrast, such effects are not manifest in other NMDA receptor inhibitors lacking this specific component, such as memantine ([@bb0350]) or 2-amino-5-phosphono-valerate (AP5) ([@bb0230]). Furthermore, we found genetic differences in NET reflected in both the cardiovascular side-effects ([@bb0225]) and in brain connectivity, further highlighting the relevance of this transporter in the mechanism of action of ketamine. Nevertheless, NMDA receptor inhibition during ketamine infusion has been shown to induce rs-fc changes in other brain areas ([@bb0210]), and we cannot exclude the possiblity that these brain regions may influence the change in LC-thalamic rs-fc.

We did not find a change of rs-fc to all brain areas that are known to be anatomically connected to the LC. However, our strong findings of altered LC-thalamic rs-fc are not surprising, considering the known functional importance of LC-thalamic connectivity ([@bb0110]) and the previously identified strong LC-thalamic rs-fc at baseline ([@bb0530]). The preferred modulation of LC-thalamic rs-fc may also be based on the high NET density found in both of these areas ([@bb0405]; [@bb0020]; [@bb0450]), and some neocortical brain areas receiving efferent projections from the LC may be modulated by other mechanisms of action of ketamine ([@bb0210]).

7. Limitations {#s0040}
==============

There are some limitations to this study. Because ketamine has transient side-effects, optimization of blinding through an active placebo control, for instance with midazolam, has been suggested ([@bb0305]). However, due to ethical considerations in a study with healthy participants, saline infusion was the most feasible option. It is not possible to measure the LC activity modes directly in human subjects. However, further research could include more indirect measurements such as pupil fluctuations or other autonomous nervous system markers that are related both to LC activity and to the dorsal attention network ([@bb0015]). We used a probabilistic template ([@bb0190]) to determine the location of the LC. Future work could include measurements of the LC location at a subject level using neuromelanine sensitive sequences ([@bb0400]; [@bb0055]). Compared to global estimation methods, including a range of frequency-domain analyses applied to multiple channels simultaneously ([@bb0515]) and independent component analysis, in which all information channels are incorporated ([@bb0265]), the seed-based rs-fc analysis applied here has the disadvantage that possible relationships and influences resulting from the interplay of multiple brain areas may be missed. However, the current approach provides the benefit of a more straightforward interpretability constrained by a priori hypotheses ([@bb0075]). While genetic studies often involve small group sample sizes, a known nearly 1:1 distribution of risk/non-risk carriers in the population ([@bb0205]) led to comparable groups for our analysis (\[AA\] *n* = 15, \[T\]-carriers *n* = 13). We did not assess ketamine plasma levels, because there are no strong indications that differences in ketamine metabolism affect psychomimetic, antidepressant or sympathomimetic effects in subjects without premedication ([@bb0355]).

Finally, our claims on antidepressant effects need substantiation in a patient group, particularly because chronic conditions such as hyperarousal may lead to a more differentiated response than the one observed in our healthy sample.

8. Conclusions {#s0045}
==============

We provide evidence that ketamine has an acute impact on brain structures known to be involved in attentional processing. We interpret our findings in the context of attentional impairment symptoms after ketamine administration and consider how they may explain aspects of its antidepressant effect. We expand our finding of *NET* rs28386840 polymorphism dependent differences in the physiological side-effects by revealing NET-dependent LC connectivity changes in the brain, further underlining the potential importance of norepinephrine in ketamine antidepressant treatment and side-effects. We suggest further research on the functional modification of brain activity by ketamine with respect to attentional processing and norepinephrine networks.
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